B-ALL in The Novel Agent Era
Tracks
-
| Sunday, April 19, 2026 |
| 10:45 AM - 12:15 PM |
| Room 12, Upper Level |
Details
In this session, Professor Fielding will give an update on the use of Blinatumomab in the next front-line B-ALL clinical trial. Dr Castleton will cover the role of Allogeneic stem cell transplant in the current era of Blinatumomab consolidation and will include the main outcomes from the RIC-ALL study. Dr Yallop will appraise CAR-T technology available in the management of Relapsed and Refractory Adult ALL.
Speaker
Dr. Anna Castleton
Consultant Haematologist
The Christie Hospital NHS Trust
The Role of Allogeneic Stem Cell Transplantation for ALL in the Novel Agent Era
10:45 AM - 11:15 AM
Dr. Deborah Yallop
Consultant Haematologist
King's College NHS Foundation Trust
CAR-T in the Management of R/R Adult ALL
11:15 AM - 11:45 AM
Prof. Adele Fielding
Professor of Haematology
University of York
Optimising outcomes using Blinatumomab in upfront B-ALL therapy
11:45 AM - 12:05 PM
Dr Michelle Lannon
Consultant Haematologist
Newcastle Hospitals NHS Foundation Trust
Session Chair
